Data Science Funding Announcements & Notices
Data science and informatics funding announcements and notices are available from NCI and NIH programs. Browse below for opportunities, requests for information, notices, and initiatives.
|Title||FOA||Organization||Release Date||Expire Date||Purpose|
|Notice of Availability of Administrative Supplements for Geospatial, Multilevel, and Contextual Approaches in Cancer Control and Population Sciences||NOT-CA-19-029||NCI||N/A||Notice Availability Administrative Supplements Geospatial, Multilevel, Contextual Approaches Cancer Control Population Sciences Notice Number: NOT-CA-19-029 Key Dates Release Date: March 12, 2019… More|
|Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)||RFA-CA-22-002||NCI||This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel… More|
|NCI Mentored Research Scientist Development Award to Promote Diversity (K01 Independent Clinical Trial Not Allowed)||PAR-21-295||NCI||This Funding Opportunity Announcement (FOA) is a continuation of the NCI Mentored Research Scientist Development Award to Promote Diversity (K01) to enhance the diversity of thought in the NCI-funded… More|
|Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U2C Clinical Trial Optional)||RFA-CA-22-010||NCI||The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U2C Resource-Related Multi… More|
|Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)||PAR-21-321||NCI||This Funding Opportunity Announcement (FOA) invites applications for P30 Cancer Center Support Grants (CCSGs) to support NCI-designated Cancer Centers. CCSGs support three types of Cancer Centers: 1… More|
|Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)||PAR-21-331||NCI||Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated studies addressing mechanisms by which bariatric… More|
|Co-infection and Cancer (R01 Clinical Trial Not Allowed)||PAR-20-062||NCI||This initiative seeks to enhance our mechanistic and epidemiologic understanding of infection-related cancers, with a focus on the etiologic roles of co-infection in cancer.
Preference will be… More
|Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R01 Clinical Trial Optional)||PAR-19-348||NCI||Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) announces its interest in supporting meritorious research projects in three distinct domains related to cancer… More|
|Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2021, 2022, and 2023 (P50 Clinical Trial Required)||PAR-20-305||NCI||Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) invites applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPORE).… More|
|Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)||PAR-19-275||NCI||This Funding Opportunity Announcement (FOA) encourages investigators to submit research grant applications that will identify, develop, test, evaluate and/or refine strategies to disseminate and… More|